Accelus Names Interim Chief Financial Officer

Accelus has recruited Greg Tibbitts to serve as interim chief financial officer (CFO). 
 
“Greg brings over 30 years of financial leadership and a proven track record of success,” Accelus President/CEO Kevin McGann said. “His expertise in managing companies of varying sizes, overseeing complex mergers, and driving significant revenue growth is invaluable. Greg’s leadership will be instrumental in driving our financial strategy and supporting our continued innovation in spinal implant technologies.”
 
Tibbitts’ career includes serving as CFO of multiple public and private companies, including Accriva Diagnostics, Accumetrics Inc., CryoCor Inc., and Elitra Pharmaceuticals. In addition to his CFO roles, Tibbitts has extensive experience in auditing and financial management. He previously was a senior auditor and senior audit manager for Ernst & Young and as a division controller for ITT Financial. He is currently a board member for Mainz Biomed, a diagnostics company, and previously held board positions with CoImmune and IDMI Pharma Inc., both biotechnologies companies.

Tibbitts earned a B.B.A. from the University of San Diego and an MBA from San Diego State University.
 
“I am excited to join Accelus as Interim CFO and contribute to its mission of delivering service to customers as a provider of minimally invasive spine solutions,” Tibbitts stated. “I look forward to working with the team to build on the company’s strong financial foundation and support its vision of enhancing surgical efficacy through innovations in lumbar spine procedures.”
 
Accelus develops expandable spinal implant technology that aims to enhancing surgical procedures and patient outcomes. The company’s advanced Adaptive Geometry technologies are specifically designed for transforaminal lumbar interbody fusion (TLIF), posterior lumbar interbody fusion (PLIF), endoscopic-assisted, percutaneous and lateral spine surgeries.